This is a routine dividend reinvestment disclosure with no trading signal. Monitor upcoming quarterly earnings and any pipeline updates for material catalysts.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 16 $52.77entry
- T+1 · 4mo ago −1.91%α −0.92% · $51.76
- T+5 · 4mo ago −3.85%α −2.18% · $50.74
- T+20 · 3mo ago −4.40%α −8.01% · $50.45
- T+60 · 6w ago −11.88%α −15.59% · $46.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a routine 6-K reporting the acquisition of ADSs by multiple PDMRs (directors and officers) through dividend reinvestment following the July 9, 2026 dividend payment. Transactions occurred on July 10 and July 14, 2026, at prices between $51.67 and $52.74, with total aggregate value of approximately $82,000. This is a standard administrative disclosure with no material financial or strategic implications.
Key Facts
- Nine PDMRs acquired ADSs via dividend reinvestment on July 10 and July 14, 2026
- Prices ranged from $51.6696 to $52.7353 per ADS
- Total shares acquired: approximately 2,036 ADSs
- Total transaction value: approximately $82,000
- Dividend paid to shareholders on July 9, 2026
Financial Impact
Approximately $82,000 in aggregate ADS acquisitions via dividend reinvestment, immaterial relative to GSK's $104B market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (GSK), Batch item 1 | 0001654954-26-006691 |
| Document: 0001654954-26-006691-index-headers.html | 0001654954-26-006691 |
| Document: 0001654954-26-006691-index.html | 0001654954-26-006691 |
| Document: 0001654954-26-006691.txt | 0001654954-26-006691 |
| 6-K Filing (GSK), Batch item 5 | 0001654954-26-006691 |
| Document: 0001654954-26-006691-index-headers.html | 0001654954-26-006691 |
| Document: 0001654954-26-006691-index.html | 0001654954-26-006691 |
| Document: 0001654954-26-006691.txt | 0001654954-26-006691 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers